It was observed in pre-clinical and clinical populations that FcRn and activating FcγR expression show no change or increase, while inhibitory FcγRIIb expression in spleen decreases in correlation with losses in skeletal muscle and lean mass in cancer. The gene discussed is FCGR2A; the disease is cancer.